Research Experience
A 12-Month Double Blind, Double-Dummy, Randomized Parallel Group, Multi-Center Efficacy, Safety Study of ——–PMDI 2X160/45 ug bid and 2X 80/45 ug bid Compared to ——2X44Sug bid and Placebo in Patients with COPD. 2003-2006
A Multi-Center, United States, Australia, Canada, and Europe, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Anemia Therapy with ——- On the Composite Event Comprising All-Cause Mortality and Cardiovascular Events in Subjects with Both CKD and Type 2 Diabetes Mellitus, 2004-2007
A 6-Month Double Blind, Randomized Parallel Group, Multi-Center, Efficacy and Safety Study of —— PMDI 2X 160/4.5 ug and 80/4.5 ug bid Compared to ——-PMDI and the Combination to Placebo in COPD Patients. 2004-2006
A Randomized, Double Blind, Placebo Controlled, Multi-Center, Phase III Study of ——20 mg in the Primary Prevention of Cardiovascular Events Among Subjects With Low Levels of LDL Cholesterol and Elevated Levels of C-Reactive Protein. 2004-2006
Impact of a Self-Adjusted Titration Guideline in Subjects with Type II Diabetes Mellitus: A 6-Month Phase IV Multi Center, Open-Label, Randomized, Parallel-Group, Treat-to-Target of Efficacy and Safety of ——(R) (Insulin Detemir [rDNA Origin] Injection). 2006-2007
A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Active Controlled, Parallel-group multi-center Trial of XXXXjXXXX Controlled Release Tablets { XXX) to Assess the Analgesic Efficacy (Compared to Placebo) in the Management of Opioid Constipation { compared to Controlled Release Tablets ( XXX) in Opioid experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Pain and a History of Opioid Induced Constipation
An Open Label Multi-Center, expanded access study of XXXX in patients with Cushing’s disease.
An Acromegaly open-label multi-center Safety monitoring program for treating patients with SOM230 (XXXX) Pasireotide LAR who have need to receive medical therapy (ACCESS) A Randomized double-blind, multi-center phase III study to evaluate the efficacy and safety of Pasireotide LAR in patients with Cushing’s disease.